| (Values in U.S. Thousands) | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 |
| Sales | 36,550 | 30,170 | 12,380 | 19,210 | 20,840 |
| Sales Growth | +21.15% | +143.70% | -35.55% | -7.82% | unch |
| Net Income | -150,720 | -84,650 | -76,130 | -39,900 | 2,330 |
| Net Income Growth | -78.05% | -11.19% | -90.80% | -1,812.45% | unch |
Prometic Life Scienc (PFSCD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada.